Entera Bio Ltd. — fact timeline

Yonatan Malca departed as Director at Entera Bio Ltd..

“Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.”

Haya Taitel departed as Director at Entera Bio Ltd..

“Each of Haya Taitel and Yonatan Malca has communicated to the Board that he or she will either resign from the Board or not stand for reelection to the Board, in either case, effective upon the date that a corresponding New Independent Director is appointed or elected to the Board.”

Entera Bio Ltd. reported financial results for three months ended March 31, 2026.

“Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended March 31, 2026.”

Entera Bio Ltd. issued 7,827,789 units of unit to funds affiliated with BVF Partners LP for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).

“On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).”

Entera Bio Ltd. entered into Purchase Agreement with funds affiliated with BVF Partners LP valued at approximately $10.0 (effective 2026-04-01).

“On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).”

Entera Bio Ltd. reported financial results for the year ended December 31, 2025.

“On March 27, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the year ended December 31, 2025 and business updates.”

Entera Bio Ltd. amended Amended and Restated Collaboration and License Agreement with OPKO Health, Inc. and OPKO Biologics Ltd. (effective 2026-02-03).

“On February 3, 2026, the Company and OPKO entered into an amended and restated collaboration and license agreement (the “ A&R Collaboration Agreement ”), which amends and restates the Original Collaboration Agreement to expand the scope of the agreement to include the collaboration with respect to the preclinical and clinical development of a daily long acting PTH tablet (“ LA-PTH ”) for the treatment of hypoparathyroidism and other indications in addition to the original oral dual agonist GLP-1/glucagon peptide program .”

Entera Bio Ltd. reported the quarter ended March 31, 2024 results: net income $2.0 million, EPS $0.05 per ordinary share (basic and diluted).

“Net loss was $2.0 million, or $0.05 per ordinary share (basic and diluted), for the period ended March 31, 2024, as compared to $2.2 million, or $0.08 per ordinary share (basic and diluted), for the period ended March 31, 2023.”

Entera Bio Ltd. reported financial results for the fiscal year ended December 31, 2023.

“On March 8 , 2024, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023.”

Entera Bio Ltd. reported financial results for the third quarter ended September 30th, 2023.

“On November 14, 2023, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023.”

Entera Bio Ltd. shareholders approved Ratification and approval of Kesselman & Kesselman (PwC Israel) as independent registered public accounting firm for FY2023 at the 2023-09-13 meeting.

“Proposal 5: Ratification and approval of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 and authorization of the Board (or the Audit Committee, if authorized by the Board) to determine such firm’s compensation in connection therewith: Votes Votes Broker For Against Abstentions Non-Votes 11,282,995 33,579 10,288 0”

Entera Bio Ltd. shareholders approved Authorization of the Board to approve an amendment to the Articles of Association to effect a reverse share split within a ratio range at the 2023-09-13 meeting.

“Proposal 4: Authorization of the Company’s Board of Directors (the “ Board ”) to, if the Board deems it necessary in order to comply with the continued listing requirements of the Nasdaq Stock Market, approve an amendment to the Articles of Association of the Company to effect a reverse share split (the “ Reverse Share Split ”) with respect to the Ordinary Shares of the Company, par value ILS 0.0000769 per share (the “ Ordinary Shares ”), at any time prior to September 13, 2024, at a ratio within a range between five (5) pre-reverse-split shares for one (1) post-reverse-split share and eleven (11) pre-reverse-split shares for one (1) post-reverse-split share (the “ Range ”), with the ratio at which the Reverse Share Split would be effected to be a ratio within the Range to be determined at the discretion of the Board and included in a public announcement by the Company before the effectiveness of the Reverse Share Split: Votes Votes Broker For Against Abstentions Non-Votes 11,060,170 2”

Entera Bio Ltd. shareholders approved Ratification and approval of a one-time grant of compensation to Ms. Haya Taitel, a Director at the 2023-09-13 meeting.

“Proposal 3: Ratification and approval of a one-time grant of compensation, as described in the Proxy Statement, to Ms. Haya Taitel, a Director: Votes Votes Broker For Against Abstentions Non-Votes 10,713,933 253,951 358,978 0”

Entera Bio Ltd. shareholders approved Ratification and approval of revised compensation items for Ms. Miranda Toledano, CEO and a Director at the 2023-09-13 meeting.

“Proposal 2: Ratification and approval of revised compensation items, as described in the Company’s Definitive Proxy Statement on Schedule 14A (the “ Proxy Statement ”) filed with the Securities and Exchange Commission on August 15, 2023, in connection with the Annual Meeting, relating to Ms. Miranda Toledano, the Company’s Chief Executive Officer and a Director: Votes Votes Broker For Against Abstentions Non-Votes 10,949,978 357,024 19,860 0”

Entera Bio Ltd. shareholders approved Election of Gerald Lieberman, Gerald Ostrov and Sean Ellis to the Board of Directors for a three-year term at the 2023-09-13 meeting.

“Proposal 1: Election of Gerald Lieberman, Gerald Ostrov and Sean Ellis to the Board of Directors of the Company for a three-year term to hold office until the Company’s 2026 Annual Meeting of Shareholders or until his successor is elected: Votes Votes Broker Director Nominee For Against Abstentions Non-Votes Gerald Lieberman 11,240,840 71,066 14,956 0 Gerald Ostrov 11,240,682 71,214 14,966 0 Sean Ellis 11,238,128 73,783 14,951 0”

Entera Bio Ltd. reported the six months ended June 30, 2023 results: net income Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023, EPS $0.16 per ordinary share (basic and diluted).

“Net loss was $4.5 million, or $0.16 per ordinary share (basic and diluted), for the six months ended June 30, 2023, as compared to $7.0 million, or $0.24 per ordinary share (basic and diluted), for the six months ended June 30, 2022.”

Entera Bio Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 29, 2023, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s ordinary shares, par value of NIS 0.0000769 per share (the “ ordinary shares ”), fail to comply with the $1.00 minimum bid price requirement for continued listing on Nasdaq in accordance with Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the ordinary shares for the 30 consecutive business days prior to the date of the Notice. Pursuant to Nasdaq Listing Rule”

Haya Taitel was appointed as Director at Entera Bio Ltd..

“On June 4, 2023, the Board of Directors (the “ Board ”) of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), expanded Class II of the Board from one to two directors and appointed Ms. Haya Taitel to fill the resulting vacancy.”

Entera Bio Ltd. reported first quarter ended March 31, 2023 results: net income Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023, EPS $0.08 per ordinary share (basic and diluted).

“Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023”

Entera Bio Ltd. reported the fiscal year ended December 31, 2022 results: revenue $134,000, net income $13.1 million, EPS $0.45 per ordinary share (basic and diluted).

“stated Miranda Toledano, Chief Executive Officer of Entera. Financial Results for the year Ended December 31, 2022 Revenues for the year ended December 31, 2022 and 2021 were $134,000 and $571,000, respectively, mainly attributable to research and development, or R&D services provided to Amgen and other third parties under material transfer agreements. The”

Entera Bio Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 21, 2022, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s ordinary shares, par value of NIS 0.0000769 per share (the “ ordinary shares ”), fail to comply with the $1.00 minimum bid price requirement for continued listing on Nasdaq in accordance with Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the ordinary shares for the 30 consecutive business days prior to the date of the Notice. Pursuant to Nasdaq Listing”

Entera Bio Ltd. reported financial results for the third quarter of 2022.

“Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,”, “our” or the “Company”), issued a press release announcing its financial results for the three and nine months ended September 30, 2022.”

Dr. Spiros Jamas departed as Chief Executive Officer at Entera Bio Ltd..

“separation from the Company of Dr. Spiros Jamas”

Miranda J. Toledano was appointed as Chief Executive Officer at Entera Bio Ltd..

“appointed Miranda J. Toledano, one of the Company’s existing directors and the Company’s Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy, as the Company’s Chief Executive Officer”

Phillip Schwartz resigned as Director at Entera Bio Ltd..

“would resign from the Company’s Board of Directors (the “Board”), effective as of the Effective Date”

Phillip Schwartz resigned as President of Research & Development at Entera Bio Ltd..

“Dr. Schwartz would resign from his position as the Company’s President of R&D, effective July 21, 2022”

Miranda J. Toledano was appointed as Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy at Entera Bio Ltd..

“appointed Ms. Miranda J. Toledano, one of the Company’s existing directors, to serve as the Company’s Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy, effective as of May 16, 2022”